Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study

Kavita R. Gajbhiye, Virendra Gajbhiye, Imtiaz A. Siddiqui, Srikanth Pilla, Vandana SoniScientific 2017 · DOI

Abstract

The aim of this work was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-b-PEG nanoparticles (NPs) using SVCT2 transporters of choroid plexus. PLGA-b-PEG copolymer was synthesized and characterized by <sup>1</sup>H NMR, gel permeation chromatography, and differential scanning calorimetry. PLGA-b-PEG-NH<sub>2</sub> and PLGA-b-mPEG NPs were prepared by nanoprecipitation method. PLGA-b-PEG NPs with desirable size, polydispersity, and drug loading were used for the conjugation with ascorbic acid (PLGA-b-PEG-Asc) to facilitate SVCT2 mediated transportation of the same into the brain. The surface functionalization of NPs with ascorbic acid significantly increased cellular uptake of NPs in SVCT2 expressing NIH/3T3 cells as compared to plain PLGA and PLGA-b-mPEG NPs. In vivo pharmacodynamic efficacy was evaluated using Morris Water Maze Test, Radial Arm Maze Test and AChE activity in scopolamine induced amnetic rats. In vivo pharmacodynamic studies demonstrated significantly higher therapeutic and sustained action by drug loaded PLGA-b-PEG-Asc NPs than free drugs and drug loaded plain PLGA as well as PLGA-b-mPEG NPs. Additionally, PLGA-b-PEG-Asc NPs resulted in significantly higher biodistribution of the drug to the brain than other formulations. Hence, the results suggested that targeting of bioactives to the brain by ascorbic acid grafted PLGA-b-PEG NPs is a promising approach.

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder primarily characterized by a significant decline in cholinergic neurotransmission. Galantamine, a potent acetylcholinesterase (AChE) inhibitor, is a standard therapeutic agent used to manage symptoms. However, its efficacy is severely limited by the blood-brain barrier (BBB), which prevents efficient drug accumulation in the central nervous system. To achieve therapeutic concentrations in the brain, high systemic doses are often required, leading to significant peripheral side effects such as gastrointestinal distress and cardiac issues.

This study addresses the challenge of brain-specific delivery by developing a "Trojan Horse" nanoparticle system. By tethering ascorbic acid (Vitamin C) to the surface of polymeric nanoparticles, the researchers aimed to exploit the SVCT2 transporters in the choroid plexus for active transport across the BBB, thereby increasing efficacy and reducing systemic toxicity.

Methodology

The researchers synthesized a specialized PLGA-b-PEG copolymer and formulated nanoparticles (NPs) using a nanoprecipitation method. The key innovation lies in the surface functionalization:

  1. Targeting Ligand: Ascorbic acid (Asc) was conjugated to the NP surface to target SVCT2 transporters, which are highly efficient at transporting Vitamin C into the brain.
  2. Stealth Coating: The PEG (polyethylene glycol) layer provides a "stealth" effect, extending the circulation time of the NPs by preventing rapid immune clearance.
  3. Drug Encapsulation: Galantamine (GLM) was loaded into the hydrophobic PLGA core.

The NPs were characterized to ensure they met the criteria for brain delivery, specifically a size of approximately 100 nm and a spherical morphology.

Characterization of the targeted nanoparticles: (A) Size distribution by intensity showing a peak at ~100 nm; (B) SEM image and (C) TEM image confirming spherical morphology and size uniformity.

Results and Discussion

In Vitro Validation

Cellular uptake studies were conducted using NIH/3T3 cells, which express the SVCT2 transporter. The targeted PLGA-b-PEG-Asc NPs demonstrated 8.51 times higher uptake compared to the free drug after 3 hours of incubation. This confirmed that the ascorbic acid coating successfully facilitates receptor-mediated endocytosis via the SVCT2 pathway.

In Vivo Efficacy

The system was evaluated in scopolamine-induced amnesic rats using several behavioral and biochemical metrics:

  • Cognitive Performance: In the Morris Water Maze, rats treated with targeted NPs showed significantly improved escape latencies (16 seconds) compared to those treated with the free drug (23 seconds) by day 5. Similar improvements were noted in the Radial Arm Maze test.
  • AChE Inhibition: The targeted NPs achieved the highest level of acetylcholinesterase inhibition in the brain, effectively restoring cholinergic function more efficiently than non-targeted formulations.
  • Biodistribution: HPLC analysis confirmed that the brain concentration of galantamine delivered via targeted NPs was approximately 19 times higher than that of the free drug solution at 24 hours post-administration.

Conclusion

The study demonstrates that ascorbic acid-functionalized PLGA-b-PEG nanoparticles are a highly effective vehicle for the targeted delivery of galantamine to the brain. By leveraging the SVCT2 transport system, this approach significantly enhances therapeutic efficacy in animal models of Alzheimer's disease while potentially minimizing peripheral side effects. This versatile platform could be adapted for the delivery of various other neuroactive compounds that are currently limited by poor BBB permeability.

Summary updated

Abstract

The aim of this work was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-b-PEG nanoparticles (NPs) using SVCT2 transporters of choroid plexus. PLGA-b-PEG copolymer was synthesized and characterized by <sup>1</sup>H NMR, gel permeation chromatography, and differential scanning calorimetry. PLGA-b-PEG-NH<sub>2</sub> and PLGA-b-mPEG NPs were prepared by nanoprecipitation method. PLGA-b-PEG NPs with desirable size, polydispersity, and drug loading were used for the conjugation with ascorbic acid (PLGA-b-PEG-Asc) to facilitate SVCT2 mediated transportation of the same into the brain. The surface functionalization of NPs with ascorbic acid significantly increased cellular uptake of NPs in SVCT2 expressing NIH/3T3 cells as compared to plain PLGA and PLGA-b-mPEG NPs. In vivo pharmacodynamic efficacy was evaluated using Morris Water Maze Test, Radial Arm Maze Test and AChE activity in scopolamine induced amnetic rats. In vivo pharmacodynamic studies demonstrated significantly higher therapeutic and sustained action by drug loaded PLGA-b-PEG-Asc NPs than free drugs and drug loaded plain PLGA as well as PLGA-b-mPEG NPs. Additionally, PLGA-b-PEG-Asc NPs resulted in significantly higher biodistribution of the drug to the brain than other formulations. Hence, the results suggested that targeting of bioactives to the brain by ascorbic acid grafted PLGA-b-PEG NPs is a promising approach.
BibTeX
@inproceedings{gajbhiye2017ascorbic,
  author = {Kavita R. Gajbhiye and Virendra Gajbhiye and Imtiaz A. Siddiqui and Srikanth Pilla and Vandana Soni},
  title = {{Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study}},
  booktitle = {Scientific},
  year = {2017},
  doi = {10.1038/s41598-017-11611-4},
}
Figure